Background: The estrogen-related receptor a (ERRa or NR3B1) is a transcription factor from the nuclear receptor super-family, group III. The gene encoding ERRa (ESRRA) is located on chromosome 11q13, a region showing genetic linkage to body mass index and fat percentage. Through interaction with the peroxisome proliferator-activated receptor-g coactivator-1a (PGC-1a), ERRa regulates key enzymes involved in the b-oxidation of fatty acids. Results: By screening 48 overweight or obese subjects for variants in the exons, exon-intron boundaries and 1000 base pairs (bp) of the promoter region of ESRRA using bi-directional nucleotide sequencing, we identified seven variants. Four rare variants had minor allele frequencies (MAF) below 1%: Pro369Pro, Gly406Asp, 3 0 UTR þ 418G4A, 3 0 UTR þ 505C4A. Two singlenucleotide polymorphisms, Pro116Pro and IVS6 þ 65C4T (MAF 15%), were in complete linkage disequilibrium (LD) (r 2 ¼ 1). We also confirmed the presence of a reported 23 bp microsatellite repeat (ESRRA23). The Pro116Pro and ESRRA23 variants were not associated with obesity, type 2 diabetes or related phenotypes in a large population-based study of 6365 Danish whites. The two variants were examined for interactions with variants in the peroxisome proliferator-activated receptor-g coactivator-1a and -b; however, no evidence of epistatic effects between the variants was demonstrated. Conclusion: The ESRRA23 and Pro116Pro variants of the gene encoding ERRa are not associated with obesity, type 2 diabetes or related quantitative traits in the examined Danish whites.
Introduction
The estrogen-related receptor a (ERRa or NR3B1) is an orphan nuclear receptor identified by close homology to the DNAbinding domain of estrogen receptor a (ERa).
1,2 ERRa belongs to the nuclear receptor super-family group III and forms a subfamily together with the estrogen-related receptor b (ERRb or NR3B2) and g (ERRg or NR3B3). 2 ERRa preferentially binds to estrogen-related response elements, termed ERREs (5 0 -TNAAGGTCA-3 0 ). Furthermore, it is able to bind and compete with the ERa for estrogen response elements (EREs). [2] [3] [4] The gene encoding ERRa (ESRRA) is located on chromosome 11q13, a chromosomal region that has shown genetic linkage to body mass index (BMI) and fat percentage. 5, 6 A pseudo gene has been identified on chromosome 13q12.1.
7
ESRRA is expressed in several tissues, but most abundantly in tissues with a high capacity for b-oxidation, such as skeletal muscle, heart, kidney, liver and adipose tissue. 1, 8 The esrra knockout (KO) mouse has reduced body weight, diminished lipogenesis in adipose cells and exhibits resistance to dietinduced obesity, indicating that ERRa may be a potent regulator of energy metabolism in vivo. 9 Specifically, through interaction with the peroxisome proliferator-activated receptor-g coactivator-1a (PGC-1a) and the peroxisome proliferator-activated receptor a (PPARa), ERRa has been reported to regulate the medium-chain acyl-CoA dehydrogenase (MCAD), an enzyme involved in the oxidation of fatty acids. [9] [10] [11] The chromosomal location, the interaction with PGC-1a in the regulation of b-oxidation and the phenotype of the esrraKO mouse make ESRRA a plausible candidate gene for metabolic diseases such as obesity and type 2 diabetes.
A 23 bp repeat (ESRRA23) in variable copy numbers (1-4 repeats) located in the promoter of ESRRA was reported to change the transcription rate of the gene. 12 The PGC-1a and ERRa bind to this repeat that contains an ERRE-binding sequence, thereby inducing the transcription of ESRRA: two ESRRA23 repeats give a sevenfold induction, whereas three ESRRA23 repeats give a 14-fold induction compared with one repeat.
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In the present study, we screened the promoter and coding regions of ESRRA for variation and examined the effect of ESRRA23 and two single-nucleotide polymorphisms (SNPs) in complete linkage disequilibrium (LD) (r 2 ¼ 1) in relation to obesity and type 2 diabetes in a large sample of Danish whites.
Materials and methods

Subjects
All participants were Danish whites by self-report and recruited from the same area of Denmark. The sampling area was 281 km 2 and had a recruitment basis of 334 500 subjects. Applying 39 biallelic SNP markers from 39 different genes and using Structure, version 2.1 (http://pritch.bsd. uchicago.edu/structure.html), we made no observation of population stratification bias in this population-based sample of white Danes. Informed written consent was obtained from all subjects before participation. The study was approved by the Ethical Committee of Copenhagen and was in accordance with the principles of the Helsinki Declaration II. The screening for genetic variants was performed on genomic DNA extracted from human leukocytes from 48 unrelated overweight or obese subjects (mean age 65710 years and BMI 31.375.1 kg/m 2 ) recruited from the outpatient clinic at Steno Diabetes Center. The number of patients included in the screening for genetic variants allows for 99.3% probability of detecting variants with a minor allele frequency (MAF) above 5%. Studies of association with obesity were carried out in the Inter99 cohort, which is a population-based randomized non-pharmacological intervention study for the prevention of cardiovascular disease conducted at the Research Centre for Prevention and Health. 13 Genomic DNA from 6360 Danish whites from this cohort was available for genotyping. These subjects were divided into three groups: (1) , 46% men, 54% women). All control persons had normal plasma glucose responses to a standardized oral glucose tolerance test. The genotype-quantitative trait studies were performed in subjects from the Inter99 cohort without diagnosed type 2 diabetes before inclusion in the study. 13 Exact numbers of subjects included in the individual studies are given in the respective tables (Tables 1a, b and 2a, b).
Anthropometrics and biochemical assays
Height and weight were measured in light indoor clothes and without shoes, and BMI was calculated as weight (kg)/ height (m) 2 . 13 Blood samples for analyses of biochemical variables were drawn in the morning after an overnight fast. Plasma glucose and serum-specific insulin (excluding des(31,32)-and intact proinsulin) were analyzed at Steno Diabetes Center using Steno Diabetes Center standard methods. 13 HbA 1C (normal range: 4.1-6.4%) was analyzed by principles of ion exchange high-pressure liquid chromatography using Bio-Rad VARIANTt HbA 1C (BioRad, Hercules, CA, USA). Serum triglycerides and total, high-density lipoprotein and low-density lipoprotein serum cholesterol were analyzed using enzymatic colorimetric methods (GPO-PAP and CHOD-PAP, Roche Molecular Biochemicals, Germany). Genetic analysis of ESRRA LH Larsen et al . Logistic regression with adjustment for age and sex was also used to calculate P-values and these were similarly nonsignificant (data not shown). 
Genetic analysis of ESRRA LH Larsen et al
Screening and genotyping
The mutation analysis for novel variants in the ESRRA (ENSG00000173153) promoter and coding region was performed using direct bidirectional nucleotide sequencing (MWG Biotech, Ebersberg, Germany) and subsequent analysis by SeqScape (Applied Biosystems, Foster City, CA, USA). The last 36 bp of exon 1 were analyzed on cDNA, as the promoter and exon 1 regions of ESRRA are very GC-rich and no polymerase chain reaction (PCR) products could be obtained of the specific segment using genomic DNA. Primers and experimental conditions are available by request to the corresponding author. Genotyping of the ESRRA 23 bp microsatellite was performed using the primers: 5 0 -CGTGGCCCCGCCCTTCC-3 0 and 5 0 -GTAGACCCAGTAGC CCCACAG-3 0 . PCR amplification was carried out in a reaction volume of 25 ml containing 50 ng genomic DNA, 1 Â PCR buffer II, 0.2 mM of each primer, 200 mM dNTP, 2.0 mM MgCl 2 and 0.7 U AmpliTaqGold DNA polymerase (Applied Biosystems). The cycle program was an initial denaturation at 951C for 15 min, followed by 40 cycles of denaturation at 951C for 30 s, annealing at 621C for 30 s and elongation at 721C for 1 min, with a final elongation step at 721C for 10 min, using a GeneAmp PCR System 9700 (Applied Biosystems). The PCR product was visualized on a 3% agarose gel for genotyping. The size of the PCR product was 140 bp for one repeat, 163 bp for two repeats, 186 bp for three repeats and 209 bp for four repeats. The Pro116Pro variant was genotyped using Taqmant (KBioscience, Hoddesdon, UK). The genotype success rates for ESRRA23 and Pro116Pro were 99.6 and 98.6%, respectively, and the mismatch rates (469 replicate samples) were 0.0 and 0.6%, respectively. The genotype distributions were in Hardy-Weinberg equilibrium.
In silico analysis of the ESRRA locus using the Ensembl database (http://www.ensembl.org/) revealed that the Pro116Pro and IVS6 þ 65C4T haplotype is not in LD with any other SNPs in the surrounding 50 kb in the European population. Two other variants were present in the ESRRA locus: an intron variant (rs731703) with an MAF of 32% and a 3 0 downstream region variant (rs4930698) with an MAF of 2% in the European population. In the entire 50 kb area used for evaluating LD around the ESRRA locus, there are 28 additional validated SNPs.
Statistical analysis
Fisher's exact test and linear regression were applied to test for significant differences in allele frequencies and genotype distributions in the obesity and type 2 diabetes case-control studies. A general linear model was used to test for differences between genotype groups in quantitative trait studies. Quantitative trait analyses were performed using Statistical Package for Social Science (SPSS, Chicago, IL., USA) version 13.0. A P-value of less than 0.05 was considered significant. Two-way interaction between variants in ESRRA, PPARGC1A and PPARGC1B was modelled using a general linear model where the parameters for marginal effects were chosen according to the significant findings. 15, 16 The epistatic parameter was estimated using the individuals for whom both risk alleles were present.
Results
We screened all seven exons, intron-exon boundaries and 1000 bp of the putative promoter of ESRRA and identified seven variants in the promoter and coding regions of ESRRA: four rare variants, Pro369Pro (c. 1107C4T), Gly406Asp (c.1217G4A), 3 0 UTR þ 418G4A, 3 0 UTR þ 505C4A, with a MAF of 1% that were not examined further owing to the low frequency in the initial analysis; two SNPs, c.348G4 A or Pro116Pro (rs2276014) and IVS6 þ 65C4T (rs11600990) (MAF 15%) that were in complete LD (r 2 ¼ 1); and one 23 bp microsatellite repeat (1-4 repeats) that was located at position À713 bp from exon 1 (GCG) in the promoter region and will be referred to as ESRRA23. The allele frequencies of the different repeats of the ESRRA23 were: one repeat, 0.03%; two repeats, 93.08%; three repeats, 6.42%; and four repeats, 0.47%. The ESRRA23 was examined for association with obesity and type 2 diabetes combining the different genotypes into short (2.1 and 2.2 repeats) and long repeats (2.3, 2.4, 3.3 and 3.4) as suggested and performed by Laflamme et al. 17 in a study of association of the ESRRA23
with bone mineral density. The analyses showed no significant association with either obesity or type 2 diabetes (Table 1a) . We also compared the 2.2 versus the 3.3 repeats and found no significant association with obesity or type 2 diabetes (data not shown). Additionally, the Pro116Pro (tagging IVS6 þ 65C4T) was examined for association with obesity and type 2 diabetes. There were no significant differences in the genotype distributions or the allele frequencies between obese and non-obese individuals or type 2 diabetes and glucose-tolerant individuals, respectively (Table 1b) . Both the ESRRA23 and the Pro116Pro were examined for association with quantitative traits related to obesity or type 2 diabetes in a population-based sample of 5926 and 5893 subjects from the Inter99 cohort, respectively (Tables 2a and  b). 13 However, the two tested variants showed no significant association with any of the related quantitative traits. When tested individually for women and men, respectively, we found that the ESRRA23 was associated with waist circumference (P ¼ 0.02) and serum triglycerides (P ¼ 0.03) men (Table 2a) . We also tested the ESRRA23 and Pro116Pro variants for interaction with the Gly482Ser variant in the gene encoding PGC-1a and the Ala203Pro, Arg265Gln and Arg292Ser polymorphisms in the gene encoding PGC1b. 15, 16 However, we failed to demonstrate any evidence of synergistic 
Discussion
Since ERRa interacts directly with PGC-1a in regulating the transcription of a key enzyme MCAD in the b-oxidation of free fatty acids, it represented an excellent candidate gene for obesity and type 2 diabetes. 9, 10 The phenotype of the esrra KO mouse also indicates that ERRa is involved in energy metabolism. 9 Similarly, the obese phenotype observed in the esra KO mouse argues that ERRa by crossreaction with EREs might play an important role in energy metabolism. 18 A recent study by Laflamme et al. 17 provided evidence that the long repeats of ESSRA23 are associated with a higher lumbar spine bone mineral density, indicating cross-regulation by ERRa and ERa of phenotypes in addition to those of energy metabolism. 17, 19 In the present study, we identified seven variants in the promoter and coding regions of ESRRA. Two of the variants, ESRRA23 and Pro116Pro, were examined for association with obesity and type 2 diabetes in large-scale case-control studies. None of the variants showed a significant association with either type 2 diabetes or obesity (Tables 1a and b) . Similarly, we were unable to demonstrate any significant associations with related quantitative traits for both sexes combined (Tables 2a and 2b) or any epistatic effect when analyzed in combination with variants in the genes encoding PGC-1a and PGC-1b. For the Pro116Pro variant, we had more than 90% statistical power to detect a relative risk of 1.3 for developing obesity or type 2 diabetes, and for the ESRRA23 with an allele frequency of the three and four repeat alleles of 7%, we had 75/90% power to detect a relative risk of 1.3/1.4. The association of ESRRA23 with triglyceride levels might be contributed to the interactions between PPARa and ERRa; 11 however, the association between ESRRA23 and triglycerides and waist circumference, respectively, in men only should be further examined in other studies to confirm these suggestive findings.
In silico analyses of 10 kb of the ESRRA locus in the European population revealed that only two additional common variants were reported: one in an intronic region and one in the 3 0 region. Extending the region to 50 kb revealed several additional SNPs. In order to examine exhaustively the ESRRA locus for association with obesity or type 2 diabetes in future studies, these SNPs are to be genotyped and haplotypes with the ESRRA variants should be formed. Additionally, epistatic effects of the ESRRA variants and variants in downstream target genes might also be included in such studies.
In conclusion, the common variants, ESRRA23 and Pro116Pro, of ESRRA are not per se or by interaction with variants in the genes encoding PGC-1a or PGC-1b contributing to an increased risk of obesity or type 2 diabetes among the examined Danish subjects.
